Reading this on a mobile device? Try our optimized mobile version here:

March 5, 2013Faster News for FasterCures

  Top News 
  • White House to Congress: Exempt FDA user fees from sequester
    The Obama administration urged Congress to allow the FDA to spend $41 billion in drugmaker user fees. The sequestration law limits the amount of fee-derived funds that the agency can spend, but experts warn that the agency will not be able to approve new drug and device applications quickly if the funds are subject to sequestration. Sequestration will slow progress toward cures and cost thousands of researchers their jobs, the White House warned. PharmaTimes (U.K.) (3/5), The Philadelphia Inquirer (2/28) LinkedInFacebookTwitterEmail this Story
  News from FasterCures 
  • Register today for March 20 Webinar on Building New Patient-Centered Research Networks
    Engaging patients in the research process is more complex and exciting now than ever before. Patient-driven organizations are moving beyond simply creating patient registries or serving as a conduit to participants for clinical trials and are marshaling their forces in new and more comprehensive ways. In this FREE webinar, part of FasterCures' ongoing series, you will learn about two new models:
    • The T1D Exchange (Presenter: Dana Ball, CEO, T1D Exchange). Consists of an integrated clinic network of more than 65 clinics across the U.S., a biorepository and Glu, an online community with mobile capabilities for people touched by type 1 diabetes.
    • Registries for All Diseases (Presenter: Sharon Terry, president and CEO, Genetic Alliance). A cross-disease, crowdsourced registry that promises to break down the silos between diseases and gather information from patients in a standardized way.
    You may submit questions for the speakers in advance when you register or by sending an e-mail to  Register today. LinkedInFacebookTwitterEmail this Story
Learn more about FasterCures ->FasterCures Home  |  Milken Institute


  Science and Technology 
  • Researchers make progress on myeloma drugs
    Two recently approved drugs promise to turn a multiple myeloma diagnosis from a death sentence to a manageable condition. The drugs, along with four older drugs, have doubled median survival time over the past decade while giving many patients good quality of life, says Dr. Brian Durie, co-founder and chairman of the International Myeloma Foundation. Researchers are working on new classes of drugs, and the Multiple Myeloma Research Foundation is conducting a study into personalized treatment combinations. The Wall Street Journal (3/4) LinkedInFacebookTwitterEmail this Story
  • Former FDA chief: Reform rules for clinical trials
    Changing the FDA's burdensome requirements for clinical trials could help double the number of new drug approvals, former FDA Commissioner Andrew von Eschenbach and University of Chicago public policy professor Tomas Philipson write. Phase III studies are unnecessarily large and cumbersome for more precise and personalized medicine. Adopting smaller, quicker adaptive studies with post-market oversight would mean greater innovation and a better economy. Bloomberg (2/28) LinkedInFacebookTwitterEmail this Story
  • Alliance aims to ease medical data sharing
    Five electronic medical records companies have formed an alliance to facilitate data sharing among hospitals and health care providers. Greenway Medical Technologies, Cerner, McKesson, Allscripts and Athenahealth will work together to develop common platforms and policies. Meanwhile, Verizon Communications announced a plan to build a secure online medical records exchange. Bloomberg (3/4) LinkedInFacebookTwitterEmail this Story
  Finance and Economics 
  • Crowd control may be necessary in new funding models
    Crowdfunding has the potential to revolutionize fundraising for early-stage life sciences, but the approach carries significant risks and limitations, write two partners and an associate at law firm McDermott Will & Emery. Different models exist, market access may be limited, fees and regulatory burdens are likely to be high, large numbers of shareholder could be problematic, and drugmakers risk losing confidentiality, the authors write. Genetic Engineering & Biotechnology News/BioPerspectives (3/4) LinkedInFacebookTwitterEmail this Story
  • Drug development and America's favorite pastime
    Drug development and baseball involve long development periods followed by short exclusivity periods for the product being developed; limited resources; assets that are traded, bought and sold; and a persistent need to find new ways to win, writes research scientist Kyle Serikawa. As in baseball, better statistical measures are improving drug development, including an emphasis on big data, Serikawa writes. Also as in baseball, "there is no way to guarantee success in drug development, and therefore, the goal is to set up the best processes, with clear measurements and benchmarks; to evaluate constantly but to intervene rarely; to work on increasing the probability of success," he writes. Xconomy/Seattle (3/1) LinkedInFacebookTwitterEmail this Story
  Policy and Regulation 
  • Europe supports push to cure rare conditions
    The European Commission will spend about $187 million on 26 research projects on rare diseases, involving research teams from 29 countries. The goal is to discover effective treatments for metabolic, immune and cardiovascular disorders, among others. PharmaTimes (U.K.) (3/1) LinkedInFacebookTwitterEmail this Story
  Society and Ethics 
  • Annual event raises funds, awareness of rare cancers
    "Saturday Night Live" star Seth Meyers, "Top Chef" host Padma Lakshmi and New York Giants linebacker Mark Herzlich were among the famous and not-so-famous participants in the annual Cycle for Survival fundraiser for rare cancer research. The event was launched in 2007 by Dave Linn and his wife, Jennifer Goodman Linn, who died of a rare soft tissue sarcoma in 2011, and has raised nearly $31 million to fund 53 different rare cancer research programs at Memorial Sloan-Kettering. HealthDay News (3/4) LinkedInFacebookTwitterEmail this Story

FasterCures / The Center for Accelerating Medical Solutions is a nonprofit think tank and catalyst for action that works across sectors and diseases to improve the effectiveness and efficiency of the medical research enterprise. FasterCures, a center of the Milken Institute, is nonpartisan and independent of interest groups.

Subscriber Tools
Print friendly format | Web version | Search past news | Briefs by date | Privacy policy

Contact Us
FasterCures / The Center for Accelerating Medical Solutions
1101 New York Avenue, NW
Suite 620
Washington, DC 20005
(202) 336-8900 |
Media Inquiries
Cecilia Arradaza
Director of Communications

 Recent FasterCures SmartBrief issues:   Lead Editor:  Lisa Gough
Distributed by:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information